
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical has potential upside drivers that may enhance its financial performance, including faster-than-expected growth in the spine market, increased sales from Enabling Technologies, and improved profit margins. Despite reported base business results of $651 million in 2Q25, reflecting a 3.3% increase, the company faced challenges with a consensus estimate of $664 million. The overall outlook remains positive, with more fundamental elements supporting growth prospects despite the recent results falling short of expectations.
Bears say
Globus Medical Inc. faces significant risks that contribute to a negative outlook, including anticipated slower growth in the spine market and potential revenue dis-synergies resulting from the NUVA merger. Furthermore, projections indicate that revenue growth may decelerate to low-single digits, which could restrict margin expansion and impact overall financial performance. In addition, weaker sales in the Enabling Technologies segment have raised concerns regarding the company's growth trajectory, as reflected in organic guidance that appears softer than expected following the recent quarter.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares